CN103134891A - Measuring method of content of butyric acid clevidipine butyrate and content of related substances - Google Patents
Measuring method of content of butyric acid clevidipine butyrate and content of related substances Download PDFInfo
- Publication number
- CN103134891A CN103134891A CN2011103920401A CN201110392040A CN103134891A CN 103134891 A CN103134891 A CN 103134891A CN 2011103920401 A CN2011103920401 A CN 2011103920401A CN 201110392040 A CN201110392040 A CN 201110392040A CN 103134891 A CN103134891 A CN 103134891A
- Authority
- CN
- China
- Prior art keywords
- content
- mobile phase
- butyrate clevidipine
- related substance
- assay method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 239000000126 substance Substances 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title abstract description 12
- KPBZROQVTHLCDU-UHFFFAOYSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-UHFFFAOYSA-N 0.000 title abstract description 4
- 229960003621 clevidipine butyrate Drugs 0.000 title abstract 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000001514 detection method Methods 0.000 claims abstract description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000945 filler Substances 0.000 claims abstract description 4
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims abstract description 4
- KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 claims description 34
- 229960003597 clevidipine Drugs 0.000 claims description 34
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 31
- 238000003556 assay Methods 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 3
- 239000000741 silica gel Substances 0.000 abstract 1
- 229910002027 silica gel Inorganic materials 0.000 abstract 1
- 238000000825 ultraviolet detection Methods 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 17
- 239000012535 impurity Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 241000206601 Carnobacterium mobile Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940010811 cleviprex Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 1
- 239000002866 dihydropyridine calcium channel blocker Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Materials By Optical Means (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Disclosed is a measuring method of the content of butyric acid clevidipine butyrate and the content of related substances. A high performance liquid chromatography is adopted, and octadecyl silane bonded silica gel is used as a reversed phase column of filler; ultraviolet detection is adopted, and detection wavelength is 230-250 nm; and a mobile phase A is acetonitrile, a mobile phase B is water, and the volume of the phase A accounts for 50%-90% of that of the mobile phases.
Description
Technical field:
The present invention relates to the assay method of a kind of butyrate clevidipine content and related substance.
Background technology:
Its chemical structural formula of clevidipine (Clevidipine, CAS:167221-71-8) is as follows:
Chemistry 4-(2,3-dichlorophenyl) by name-Isosorbide-5-Nitrae-dihydro-2,6-dimethyl-3,5-dipicolinic acid methyl (1-oxo butoxy) methyl ester is a kind of fugitive dihydropyridine calcium channel blocker.The butyrate clevidipine emulsion for injection is that Britain Astrazeneca AB develops, U.S. The Medicines Company company has it in exploitation and the commercialization mandate of the world market except Japan, and in August, 2008 first in U.S.'s listing this product, trade name Cleviprex, be used for the invalid hyperpietic's of unsuitable oral drugs or oral drugs treatment, after also can be used for treating operation, acute blood pressure raises, and this medicine is the first intravenous injection antihypertensive of drugs approved by FDA over 10 years.Animal experiment shows, it can descend mean arterial pressure by reducing systemic vascular resistance, to the VC blood vessel without effect.The III clinical trial phase of butyrate clevidipine intravenous injection emulsion has obtained the certainty result, studies show that, after Perioperative Hypertension patient medication in 15 minutes systolic pressure descend gradually, medication reached steady-state level after 15 minutes, after medication in 30 minutes changes in heart rate substantially steady, or slightly accelerate.
At present about the bibliographical information of the content assaying method of butyrate clevidipine seldom.The people such as Olle Gyllenhaal are at JChromatogr Nov 5 A.1999; 862 (1): reported in 95-104 to adopt and filled the purity that the pillar supercritical fluid chromatography detects clevidipine, yet the requirement of this method flow phase is harsher, equipment requirement is higher, and the prior application of supercritical fluid chromatography is to be used for to separate and preparation, application aspect analyzing and testing is also not universal, is not suitable for industrialized needs.In existing bibliographical information, have no other about the report of the assay method of butyrate clevidipine content and related substance.
Summary of the invention:
For overcoming defective of the prior art, this patent adopts high performance liquid chromatography, and using the most general anti-phase C18 post is the separation chromatography post, has realized the assay of butyrate clevidipine, and method is easy, accurate, good reproducibility.
The invention provides the assay method of a kind of butyrate clevidipine content and related substance:
A. be the reverse-phase chromatographic column of filling agent with octadecylsilane chemically bonded silica;
B. ultraviolet detects, and the detection wavelength is 230～250nm, is preferably 239～241nm, most preferably 240nm;
C. mobile phase A is acetonitrile mutually, and Mobile phase B is water mutually, and the volume ratio that A accounts for mobile phase mutually is 50%～90%, and is preferred 60%～80%, most preferably 70%;
D. chromatogram column temperature between 20～50 ℃, is preferably 30 ℃.
Preferably
Testing conditions is:
The detection wavelength is 240nm;
Detected temperatures is 30 ℃;
Mobile phase: the volume ratio of acetonitrile and water is 70: 30.
Or testing conditions is:
The detection wavelength is 239nm;
Detected temperatures is 30 ℃;
Mobile phase: the volume ratio of acetonitrile and water is 60: 40.
Or testing conditions is:
The detection wavelength is 241nm;
Detected temperatures is 40 ℃;
Mobile phase: the volume ratio of acetonitrile and water is 80: 20.
The analytical approach that the present invention mentions, its flow rate of mobile phase are set as the known general knowledge of those skilled in the art.Common scope is generally between 0.5ml/min to 2ml/min.
The chromatogram that the analytical approach that the present invention mentions obtains is the normalization method liquid chromatogram of specimen, obtained the normalization method liquid content of specimen, use same analytical approach, the normalization method liquid content of the reference substance that can obtain testing, then calculate the liquid content that can obtain butyrate clevidipine by external standard method, can measure related substance by Self-control method.
" chemicals Quality Control Analysis method validation technological guidance principle " ([H] GPH5-1) that promulgate according to State Food and Drug Administration carries out the methodology checking to above-mentioned analysis condition, proves that content and the related substance of the method mensuration butyrate clevidipine complies with relevant regulations.
The efficient liquid-phase chromatography method of the content detection of butyrate clevidipine provided by the invention has following advantage:
(1) use common octadecylsilane chemically bonded silica to be the chromatographic column of filling agent, equipment requirement is not high.
(2) mobile phase is selected acetonitrile and water, two common being easy to get of medium, and feasibility is high.
(3) operating process is simple and convenient, accurately, and good reproducibility.
(4) applicability is good, can detect simultaneously content and the related substance of butyrate clevidipine.
Description of drawings:
Fig. 1: embodiment 1 gained liquid chromatogram
Fig. 2: embodiment 2 gained liquid chromatograms
Fig. 3: embodiment 3 gained liquid chromatograms
Fig. 4: embodiment 4 gained liquid chromatograms
Fig. 5: embodiment 5 gained liquid chromatograms
Embodiment:
The below will the invention will be further described by embodiment, and these descriptions are not that content of the present invention is done further to limit.Person skilled should be understood that and is equal to replacement to what technical characterictic of the present invention was done, or corresponding the improvement, within still belonging to protection scope of the present invention.
The reference substance of butyrate clevidipine reaches 99.90% for the self-control sample by internal mark method determination content.
The configuration of sample solution: precision measures each 20.0mg of butyrate clevidipine sample 1-5, is placed in the 100ml measuring bottle, after adding the dissolving of appropriate acetonitrile-water (7: 3) mixed solution, is diluted to scale with acetonitrile-water (7: 3) mixed solution.
The configuration of content reference substance solution: precision measures butyrate clevidipine reference substance 20.0mg, is placed in the 100ml measuring bottle, after adding the dissolving of appropriate acetonitrile-water (7: 3) mixed solution, is diluted to scale with acetonitrile-water (7: 3) mixed solution.
The configuration of impurity reference substance solution: the above-mentioned content reference substance solution of separately getting 1ml is diluted to the 100ml volumetric flask with acetonitrile-water (7: 3) mixed solution.
With above-mentioned sample solution and reference substance solution difference sample introduction, provide HPLC to analyze according to following condition, external standard method is calculated butyrate clevidipine content, and Self-control method detects related substance.
Embodiment 1
Chromatographic condition:
High performance liquid chromatograph: Waters-2489-2695
Detecting device: UV-detector detects wavelength: 240nm
Sample size: 20.0 μ l column temperatures: 30 ℃
Flow velocity: the 1ml/min post is pressed: 1250psi
Chromatographic column: Agilent, C18,5 μ m, 4.6 * 250mm
Analytical balance: 100,000/, Sartorius BS21S
Mobile phase: acetonitrile: water=70: 30
Measurement result (Fig. 1):
| Title | Retention time (minute) | Content (%) |
| Butyrate clevidipine | 7.771 | 99.88 |
| Impurity 1 | 3.865 | 0.05 |
| Impurity 2 | 6.136 | 0.03 |
| Impurity 3 | 10.118 | 0.04 |
Embodiment 2
Chromatographic condition:
High performance liquid chromatograph: Waters-2489-2695
Detecting device: UV-detector detects wavelength: 230nm
Sample size: 20.0 μ l column temperatures: 50 ℃
Flow velocity: the 1ml/min post is pressed: 1250psi
Chromatographic column: Agilent, C18,5 μ m, 4.6 * 250mm
Analytical balance: 100,000/, Sartorius BS21S
Mobile phase: acetonitrile: water=50: 50
Measurement result (Fig. 2):
| Title | Retention time (minute) | Content (%) |
| Butyrate clevidipine | 8.025 | 99.73 |
| Impurity 1 | 3.133 | 0.01 |
| Impurity 2 | 5.764 | 0.15 |
| Impurity 3 | 11.690 | 0.11 |
Embodiment 3
Chromatographic condition:
High performance liquid chromatograph: Waters-2489-2695
Detecting device: UV-detector detects wavelength: 239nm
Sample size: 20.0 μ l column temperatures: 30 ℃
Flow velocity: the 1ml/min post is pressed: 1250psi
Chromatographic column: Agilent, C18,5 μ m, 4.6 * 250mm
Analytical balance: 100,000/, Sartorius BS21S
Mobile phase: acetonitrile: water=60: 40
Measurement result (Fig. 3):
| Title | Retention time (minute) | Content (%) |
| Butyrate clevidipine | 7.829 | 99.90 |
| Impurity 1 | 3.890 | 0.03 |
| Impurity 2 | 6.177 | 0.03 |
| Impurity 3 | 10.202 | 0.04 |
Embodiment 4
Chromatographic condition:
High performance liquid chromatograph: Waters-2489-2695
Detecting device: UV-detector detects wavelength: 250nm
Sample size: 20.0 μ l column temperatures: 20 ℃
Flow velocity: the 1ml/min post is pressed: 1250psi
Chromatographic column: Agilent, C18,5 μ m, 4.6 * 250mm
Analytical balance: 100,000/, Sartorius BS21S
Mobile phase: acetonitrile: water=90: 10
Measurement result (Fig. 4):
| Title | Retention time (minute) | Content (%) |
| Butyrate clevidipine | 7.263 | 99.50 |
| Impurity 1 | 3.892 | 0.05 |
| Impurity 2 | 5.823 | 0.27 |
| Impurity 3 | 9.311 | 0.18 |
Embodiment 5
Chromatographic condition:
High performance liquid chromatograph: Waters-2489-2695
Detecting device: UV-detector detects wavelength: 241nm
Sample size: 20.0 μ l column temperatures: 40 ℃
Flow velocity: the 1ml/min post is pressed: 1250psi
Chromatographic column: Agilent, C18,5 μ m, 4.6 * 250mm
Analytical balance: 100,000/, Sartorius BS21S
Mobile phase: acetonitrile: water=80: 20
Measurement result (Fig. 5):
| Title | Retention time (minute) | Content (%) |
| Butyrate clevidipine | 7.452 | 99.19 |
| Impurity 1 | 3.942 | 0.02 |
| Impurity 2 | 5.943 | 0.58 |
| Impurity 3 | 9.611 | 0.21 |
Claims (10)
1. the assay method of a butyrate clevidipine content and related substance, it is characterized in that: be the reverse-phase chromatographic column of filling agent with octadecylsilane chemically bonded silica, the detection wavelength is 230～250nm, mobile phase A is acetonitrile mutually, Mobile phase B is water mutually, and the volume ratio that A accounts for mobile phase mutually is 50%～90%.
2. the assay method of butyrate clevidipine content as claimed in claim 1 and related substance, it is characterized in that: detection wavelength used is preferably 239～241nm.
3. the assay method of butyrate clevidipine content as claimed in claim 2 and related substance, it is characterized in that: detection wavelength used most preferably is 240nm.
4. the assay method of butyrate clevidipine content as claimed in claim 1 and related substance, it is characterized in that: the volume ratio that mobile phase A accounts for mobile phase mutually is preferably 60%～80%.
5. the assay method of butyrate clevidipine content as claimed in claim 4 and related substance, it is characterized in that: the volume ratio that mobile phase A accounts for mobile phase mutually most preferably is 70%.
6. the assay method of described butyrate clevidipine content as arbitrary in claim 1～5 and related substance, it is characterized in that: chromatogram column temperature is between 20～50 ℃.
7. the assay method of butyrate clevidipine content as claimed in claim 6 and related substance, it is characterized in that: chromatogram column temperature is preferably 30 ℃.
8. the assay method of butyrate clevidipine content as claimed in claim 1 and related substance, it is characterized in that: testing conditions is as follows:
The detection wavelength is 240nm;
Detected temperatures is 30 ℃;
Mobile phase: the volume ratio of acetonitrile and water is 70: 30.
9. the assay method of butyrate clevidipine content as claimed in claim 1 and related substance, it is characterized in that: testing conditions is as follows:
The detection wavelength is 239nm;
Detected temperatures is 30 ℃;
Mobile phase: the volume ratio of acetonitrile and water is 60: 40.
10. the assay method of butyrate clevidipine content as claimed in claim 1 and related substance, it is characterized in that: testing conditions is as follows:
The detection wavelength is 241nm;
Detected temperatures is 40 ℃;
Mobile phase: the volume ratio of acetonitrile and water is 80: 20.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103920401A CN103134891A (en) | 2011-11-30 | 2011-11-30 | Measuring method of content of butyric acid clevidipine butyrate and content of related substances |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103920401A CN103134891A (en) | 2011-11-30 | 2011-11-30 | Measuring method of content of butyric acid clevidipine butyrate and content of related substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103134891A true CN103134891A (en) | 2013-06-05 |
Family
ID=48494995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103920401A Pending CN103134891A (en) | 2011-11-30 | 2011-11-30 | Measuring method of content of butyric acid clevidipine butyrate and content of related substances |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103134891A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104458937A (en) * | 2014-11-20 | 2015-03-25 | 北京京科泰来科技有限公司 | Method for detecting related substances in cleviprex fat emulsion |
| CN104597192A (en) * | 2014-12-31 | 2015-05-06 | 武汉科福新药有限责任公司 | Method for detecting clevidipine butyrate and related substances in preparations of clevidipine butyrate |
| CN104833670A (en) * | 2015-05-13 | 2015-08-12 | 中国人民解放军第二军医大学 | Real-time monitoring method for clevidipine butyrate crude drug synthesis process |
| CN105092769A (en) * | 2015-01-15 | 2015-11-25 | 上海馨平医药科技发展有限公司 | Method for simultaneously detecting clevidipine butyrate and related substances |
| CN107367569A (en) * | 2016-05-13 | 2017-11-21 | 天津康鸿医药科技发展有限公司 | A kind of detection method of butyrate clevidipine about material |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010014234A1 (en) * | 2008-08-01 | 2010-02-04 | The Medicines Company | Pharmaceutical compositions and methods for stabilizing the same |
| CN102170786A (en) * | 2008-08-01 | 2011-08-31 | 医药公司 | Pharmaceutical compositions and methods for producing low impurity concentrations of the same |
-
2011
- 2011-11-30 CN CN2011103920401A patent/CN103134891A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010014234A1 (en) * | 2008-08-01 | 2010-02-04 | The Medicines Company | Pharmaceutical compositions and methods for stabilizing the same |
| CN102170786A (en) * | 2008-08-01 | 2011-08-31 | 医药公司 | Pharmaceutical compositions and methods for producing low impurity concentrations of the same |
Non-Patent Citations (3)
| Title |
|---|
| OLLE GYLLENHAAL ET AL: "Packed-column supercritical fluid chromatography for the purity analysis of clevidipine, a new dihydropyridine drug", 《JOURNAL OF CHROMATOGRAPHY A》 * |
| 张婧 等: "氯维地平的合成", 《中国医药工业杂志》 * |
| 邓超 等: "丁酸氯维地平成品中杂质的合成与结构鉴定", 《现代药物与临床》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104458937A (en) * | 2014-11-20 | 2015-03-25 | 北京京科泰来科技有限公司 | Method for detecting related substances in cleviprex fat emulsion |
| CN104597192A (en) * | 2014-12-31 | 2015-05-06 | 武汉科福新药有限责任公司 | Method for detecting clevidipine butyrate and related substances in preparations of clevidipine butyrate |
| CN105092769A (en) * | 2015-01-15 | 2015-11-25 | 上海馨平医药科技发展有限公司 | Method for simultaneously detecting clevidipine butyrate and related substances |
| CN104833670A (en) * | 2015-05-13 | 2015-08-12 | 中国人民解放军第二军医大学 | Real-time monitoring method for clevidipine butyrate crude drug synthesis process |
| CN104833670B (en) * | 2015-05-13 | 2017-08-01 | 中国人民解放军第二军医大学 | A kind of real-time monitoring method of clevidipine butyrate crude drug synthesis process |
| CN107367569A (en) * | 2016-05-13 | 2017-11-21 | 天津康鸿医药科技发展有限公司 | A kind of detection method of butyrate clevidipine about material |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105334274B (en) | Reversed-phase high performance liquid chromatography determination method for content and related substances of tofacitinib citrate | |
| CN103134891A (en) | Measuring method of content of butyric acid clevidipine butyrate and content of related substances | |
| CN101502616B (en) | Method for measuring content of Bletilla striata medicinal materials | |
| CN102375033B (en) | High performance liquid chromatographic analysis method of bendamustine hydrochloride and its related substances | |
| CN102445500B (en) | Method for detecting macromolecular substances in Yiqifumai injection | |
| CN104597192A (en) | Method for detecting clevidipine butyrate and related substances in preparations of clevidipine butyrate | |
| CN105301123B (en) | A kind of HPLC detection methods of Liangfu class preparation | |
| CN104678006B (en) | Sunitinib malate related substance analysis method | |
| CN108414636A (en) | A kind of detection method of the cinnarizine in relation to substance | |
| CN105572275A (en) | Dabigatran etexilate mesylate content detection method | |
| Hussain et al. | Quantitation of metronidazole in pharmaceutical suspension using high performance liquid chromatographic method | |
| CN105424834B (en) | Detect 2-Pyrrolidone and formic acid method in PVP K30 simultaneously | |
| Bonfilio et al. | Multivariate development and validation of a stability-indicating HPLC method for the determination of glimepiride in tablets | |
| CN110596274B (en) | Method for detecting 2-mercaptobenzothiazole in ceftriaxone sodium | |
| CN104950047A (en) | Method for detecting content, dissolution rate and releasing rate of memantine hydrochloride or analogues thereof in medicinal agent | |
| CN101285802B (en) | Qualitative analysis detection method for high polarity sugar-reducing chemical medicament in traditional Chinese medicine | |
| CN107389821A (en) | A kind of method of active ingredient in measure ageratum oral liquid | |
| Garcia-Martínez et al. | Bionalytical validation study for the determination of unbound ambrisentan in human plasma using rapid equilibrium dialysis followed by ultra performance liquid chromatography coupled to mass spectrometry | |
| Nguyen et al. | Rapid and simultaneous determination of paracetamol, ibuprofen and related impurity of ibuprofen by UPLC/DAD | |
| CN104965031B (en) | Content measuring method for compound ketoprofen and omeprazole sustained-release capsules | |
| CN102590408B (en) | Method for detecting macromolecular substances in perhexiline injection | |
| CN106153756B (en) | High performance liquid chromatography for detecting rapamycin in everolimus | |
| CN104807898A (en) | HPLC (High Performance Liquid Chromatography) method for determining dissolution rate of Lercanidipine hydrochloride tablet | |
| CN102928525A (en) | Method for detecting related substance II of cefpirome in cefpirome sulfate/sodium chloride injection | |
| CN115656364A (en) | Detection method of related substances in rifampicin and application of detection method in MNP (MNP) monitoring |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130605 |